skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Figitumumab (Code C52187)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Figitumumab

Definition: A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. Figitumumab selectively binds to IGF1R, preventing insulin-like growth factor type 1 (IGF1) from binding to the receptor and subsequent receptor autophosphorylation. Inhibition of IGF1R autophosphorylation may result in a reduction in receptor expression on tumor cells that express IGF1R, a reduction in the anti-apoptotic effect of IGF, and inhibition of tumor growth. IGF1R is a receptor tyrosine kinase expressed on most tumor cells and is involved in mitogenesis, angiogenesis, and tumor cell survival.

Display Name: Figitumumab

Label: Figitumumab

NCI Thesaurus Code: C52187 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2713009  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
CP-751,871
CP-751871
Figitumumab
FIGITUMUMAB

External Source Codes: 
CAS Registry Number 943453-46-1 (see NLM ChemIDplus info)
FDA UNII Code VE267FC2UB
PDQ Closed Trial Search ID 456793
PDQ Open Trial Search ID 456793 (check for NCI PDQ open clinical trial info)
UMLS CUI C2713009

Other Properties:
     Name Value (qualifiers indented underneath)
code C52187
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name CP-751871
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C52187

Mainbox Bottom